Ranolazine
- TRADE NAME: Ranexa (CV Therapeutics)
- INDICATIONS: Angina
- CLASS: Anti-ischemic, Fatty acid oxidation inhibitor
- HALF-LIFE: 7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Clarithromycin, Conivaptan, Cyclosporine, CYP3A inducers, CYP3A inhibitors, Darunavir, Delavirdine, Diltiazem, Dofetilide, Efavirenz, Erythromycin, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Oxcarbazepine, Paroxetine Hydrochloride, Phenobarbital, Quinidine, Rifampin, Rifapentine, Ritonavir, Simvastatin, Sotalol, Telithromycin, Thioridazine, Tipranavir, Venetoclax, Verapamil, Voriconazole, Ziprasidone
PREGNANCY CATEGORY: C
Contra-indicated in patients with existing QT prolongation, and in patients with liver disease.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
MULTI-ORGAN AND/OR MULTI-METABOLIC ADVERSE REACTIONS.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric